Furthermore, we found that the expression of PD-L2, CD80, CD86, and CTLA-4 are also elevated in cytomegalovirus and EBV-positive tumor patients, suggesting anti-PD-L2 and anti-CTLA4 immunotherapy may be effective in patients with these types of tumors. Here, PDCD1LG2 is linked to neoplasm.